Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celltrion, Inc.
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Korea's New Fast Track Scheme A GIFT For High-Need Drugs
South Korea designates two more global innovative products for support under a new fast track system, in a move set to speed up patient access to novel therapies.
Next Potential Big ADC Player? Korean Firms Take It Up A Notch
Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.
Celltrion Allies With Rani As Exclusive Oral Ustekinumab Partner
Having previously an agreement with BioFactura to assess the company’s proposed ustekinumab biosimilar with its RaniPill oral drug delivery technology, Rani has now unveiled a deal with Korean major Celltrion for use of its CT-P43 Stelara biosimilar candidate.
- Generic Drugs
- OTC, Consumer
- Large Molecule
- Other Names / Subsidiaries
- Bio CDMO
- Celltrion Healthcare Hungary Kft
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.